In this prospective study of children with Lennox-Gastaut syndrome receiving clobazam as adjunctive therapy, researchers tested medication efficacy as it relates to seizure reduction as well as improvement in the behavior and quality of life (QOL) reported by parents.
In this 6-week, 4 phase study, they involved 10 patients with Lennox-Gastaut syndrome (aged 3-11 years). Patients exhibited improvement on indices of QOL, including physical activities, well-being, cognition, social activities, behavior, general health, and overall QOL.
The Quality of Life in Childhood Epilepsy (QOLCE) questionnaire showed significant improvement in cognition, social activities, behavior, and overall QOL. An improvement was observed in all patients with documented baseline seizures (8/10), with 5 showing significant improvement (95%-100% reduction) and 3 showing minor improvement (7%-23% reduction). In patients with clobazam, an overall trend towards positive well-being was seen as an adjunct therapy in children for Lennox-Gastaut syndrome.